Los Angeles – Dec 14, 2023
Terray Therapeutics, a leader in AI-driven small molecule discovery, has entered into a multi-target research collaboration with Bristol Myers Squibb (NYSE: BMY) to advance the development of next-generation therapeutics. Leveraging Terray’s proprietary tNova platform, the partnership aims to identify novel small molecule candidates for diseases with significant unmet needs.
Strategic Partnership to Advance AI-Driven Drug Discovery
As part of the agreement, Terray will deploy its generative AI-enabled drug discovery engine to identify and optimize small molecule compounds against select targets designated by Bristol Myers Squibb. Following early-stage discovery efforts, Bristol Myers Squibb will lead further development and global commercialization. Terray will receive an upfront payment, milestone-based compensation for research and clinical progress, and tiered royalties on commercialized products.
Leadership Perspectives on the Collaboration
“This collaboration underscores the transformative potential of our platform in accelerating drug discovery,” said Jacob Berlin, Ph.D., CEO of Terray Therapeutics. “By combining our precision-driven AI approach with Bristol Myers Squibb’s deep expertise in drug development, we aim to unlock new possibilities for small molecule therapeutics.”
Harnessing Generative AI for Drug Discovery
Terray’s tNova platform integrates large-scale experimentation, AI-driven molecular optimization, and computational insights to redefine small molecule discovery. By generating high-resolution, purpose-built datasets, Terray enhances molecular profiling and accelerates the identification of promising drug candidates.
Shaping the Future of Small Molecule Therapeutics
With this collaboration, Terray and Bristol Myers Squibb are driving a new era of AI-powered drug discovery—transforming the efficiency, accuracy, and success rates of small molecule therapeutics.
About Terray Therapeutics
Terray Therapeutics is a biotechnology company pioneering a data-driven approach to small-molecule drug discovery. By integrating ultra-high throughput experimentation, generative AI, medicinal chemistry, and nanotechnology, Terray’s platform enables rapid and efficient identification of promising drug candidates. The company’s tNova platform blends large-scale proprietary experimental data with AI-driven insights to advance the next generation of precision therapeutics. More about news
By
